Peripherally inserted central catheters and upper extremity deep vein thrombosis.

Upper extremity deep vein thrombosis is a known complication in patients with central venous access. Prior research has shown that central lines contribute to this risk. However, the exact incidence and contributing factors remain unclear. No prior work had resolved the specific role of peripherally inserted central catheters in this context. Some studies suggest a link between malignancy and thrombosis, but evidence is inconsistent. Chemotherapy use has also been associated with increased clotting risk. The mechanisms behind this association are not fully understood. This gap motivated a detailed analysis of clinical records to clarify risk profiles. Understanding these factors may improve patient management strategies.

The study aimed to evaluate the frequency of upper extremity deep vein thrombosis in patients with peripherally inserted central catheters. It focused on identifying specific risk factors linked to this condition. Researchers reviewed clinical records from a vascular medicine department. They examined venous duplex scan results between 2000 and 2002. The goal was to determine which patient characteristics correlated with thrombosis. Chemotherapy use and malignancy were considered as potential contributors. The study also compared outcomes for different catheter purposes. This approach allowed for a focused analysis of high-risk scenarios.

A retrospective chart review was conducted in a vascular medicine department. Venous duplex scans from 2000 to 2002 were analyzed for thrombosis. Researchers identified 317 upper extremity scans for evaluation. Of these, 115 showed evidence of deep vein thrombosis. Patient records were reviewed to extract relevant clinical data. Central line presence, malignancy, and chemotherapy were recorded. Symptomatic versus asymptomatic cases were differentiated. The analysis compared thrombosis rates based on catheter purpose.

Of the 317 scans, 115 showed upper extremity deep vein thrombosis. This corresponds to a 32% incidence rate in the study population. Three main risk factors were identified: central lines, malignancy, and chemotherapy. Peripherally inserted central catheters were the most common central line type. Patients receiving chemotherapy through PICCs had a 10% thrombosis rate. Symptomatic cases occurred in 7% of chemotherapy-related PICC placements. Only 1% of non-chemotherapy PICCs led to symptomatic thrombosis. Post-thrombotic syndrome was rare in the affected patients.

Patients with peripherally inserted central catheters face a 32% risk of upper extremity deep vein thrombosis. Chemotherapy administration through PICCs increases this risk to 10%. Malignancy and central line presence are significant contributing factors. The study suggests a possible benefit for low-dose anticoagulation in high-risk cases. Symptomatic thrombosis was more common in chemotherapy-related PICC use. Post-thrombotic syndrome was not a frequent complication in this cohort. These findings highlight the need for targeted monitoring strategies. The authors propose further investigation into prophylactic interventions.